Two reviews published weeks apart in early 2026 asked the same question about GLP-1 receptor agonists and sexual function and came back with a contradiction that the hormone panels do not resolve. Total testosterone rises on these drugs — a meta-analysis of seven studies and 680 men put the standardised mean difference at 1.39 ng/mL (95% CI 0.70–2.09, p < 0.0001), with LH and FSH rising alongside it (PMID 40105090). On paper that is the profile of a man whose libido should be improving. The narrative review in Sexual Medicine Reviews and the clinical review in Obesity Pillars both document the opposite complaint arriving in clinic anyway.
The reconciliation candidate sitting in the data is unglamorous: sex hormone-binding globulin rises in step with total testosterone, and free testosterone — the bioavailable fraction — moves inconsistently as a result (PMID 41498523). A normal-looking total-T result and a flat free-T result can coexist with the complaint, which is one reason the effect is difficult to see from a lab slip. The second candidate is a serotonergic mechanism at the 5-HT2C receptor, the same pathway implicated in SSRI-associated sexual dysfunction (PMID 41404471).
Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Semaglutide, tirzepatide and liraglutide are active ingredients in FDA-approved prescription products; the research-peptide and compounded forms discussed and linked below are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
The two 2026 reviews
The first is a structured narrative review by Merhi, published in Sexual Medicine Reviews on 5 January 2026 (PMID 41870138). It synthesises preclinical and clinical evidence on GLP-1 receptor agonists, libido and sexual function in both sexes, and its central finding is a divergence between the animal work and the human work.
In rodents, the signal is consistent. The GLP-1 receptor agonist exendin-4 suppressed sexual interaction behaviours in a brain-region-specific manner — the laterodorsal tegmental area, the posterior ventral tegmental area, and the nucleus accumbens shell, all reward-circuit structures. Activation of the nucleus of the solitary tract reduced pre-sexual, sexual and post-sexual behaviours, accompanied by elevated corticosterone and altered monoamine turnover. The review reads that as diminished sexual motivation operating through neuroendocrine and stress-related mechanisms rather than through anything peripheral.
In humans the picture fragments. Pharmacovigilance analysis of the FDA Adverse Event Reporting System turned up reports of erectile dysfunction, decreased libido and orgasmic dysfunction among GLP-1 receptor agonist users — but the disproportionality analysis on those reports came back statistically insignificant, meaning the reports were not arriving at a rate above background. A netnographic analysis of user posts on social media found self-reported reductions in substance use and compulsive behaviours alongside genuinely variable libido effects: some users attributing enhancement to weight loss and improved body image, others describing decreased desire. And a randomised, double-blind crossover trial of dulaglutide in healthy lean men found no effect on sexual desire, HPG-axis hormones or semen parameters at all.
The second review is Gelfand, Tveit and Simon in Obesity Pillars, indexed for March 2026 (PMID 41404471). Rather than resurveying the outcome data, it proposes a mechanism and then explains why the effect would be hard to observe even if it were real.
| Line of evidence | What it reports | Direction |
|---|---|---|
| Rodent reward-circuit studies (exendin-4) | Suppressed sexual interaction behaviours, region-specific | Desire down |
| FAERS pharmacovigilance | ED, decreased libido, orgasmic dysfunction reported; disproportionality null | No signal |
| Dulaglutide RCT, healthy lean men | No effect on desire, HPG hormones or semen | No effect |
| Netnographic social-media analysis | Variable — both enhancement and reduction self-reported | Mixed |
| Male hormone meta-analysis, n = 680 | Total testosterone SMD +1.39 ng/mL, LH and FSH up | Desire up |
| Systematic review, n = 639 | Free testosterone inconsistent, offset by SHBG rise | Flat |
| Case reports with rechallenge | FSFI 12.7 on drug, 28.7 off, 14.7 on rechallenge | Desire down |
The 5-HT2C model, and why nobody sees it
The proposed pathway is serotonergic. The review argues that GLP-1 receptor agonist modulation raises serotonergic activity at the 5-HT2C receptor, and that increased 5-HT2C tone carries an associated negative effect on sexual desire. That receptor is not an obscure choice — 5-HT2C agonism is the mechanism most often invoked to explain SSRI-associated sexual dysfunction, which is among the best-characterised drug-induced desire effects in the literature.
What makes the paper useful is the second half of its argument. The authors describe a set of competing influences that camouflage the effect in practice. Working against desire: the serotonergic pathway itself, the gastrointestinal side effects that affect up to half of patients on these agents, and the rise in sex hormone-binding globulin. Working for it: rising total testosterone, improved vascular reactivity, and improved mood. Net out a physiological suppressor against three enhancers in a patient who is also losing weight and reporting better body image, and the suppressor disappears into the noise — for the patient and the clinician both.
Their closing point is a measurement complaint rather than a clinical one. Sexual desire is not systematically collected or reported as an adverse outcome in GLP-1 trials, so the question of whether it changes has never actually been asked at scale. That is the gap this entire literature sits in.
What the hormone data shows
The male endocrine picture is the part with real statistical weight behind it, and it runs the other direction.
Salvio and colleagues published a systematic review and meta-analysis in Andrology in November 2025 covering seven studies and 680 men (PMID 40105090). Treatment with GLP-1 receptor agonists produced a significant increase in total serum testosterone, standardised mean difference 1.39 ng/mL (95% CI 0.70–2.09, p < 0.0001). Free testosterone, SHBG, LH and FSH all showed similar increases, while weight, BMI, waist circumference and HbA1c fell. Meta-regression found a significant negative correlation between the change in total testosterone and the percentage change in weight and BMI — the more weight came off, the larger the testosterone gain. Compared against other antidiabetic and weight-lowering regimens, GLP-1 receptor agonists showed comparable androgen effects but greater BMI reduction and greater increases in gonadotropins and erectile-function indices. The authors were explicit that the literature does not allow a direct testicular action to be demonstrated; the effect may be entirely downstream of weight loss.
Deameh and colleagues published a systematic review in the Journal of Sexual Medicine on 7 January 2026 covering 10 studies and 639 men on liraglutide, semaglutide, dulaglutide and exenatide (PMID 41498523). Total testosterone rose consistently, most clearly in men with obesity, type 2 diabetes or functional hypogonadism. Free testosterone changes were inconsistent, and the review attributes that specifically to concurrent rises in SHBG. LH and FSH were preserved or increased — which the authors contrast against the suppression seen in testosterone-therapy comparator groups, and which is the basis for their framing of GLP-1 receptor agonists as a potentially fertility-sparing alternative in obesity-related hypogonadism. Semen parameter improvements appeared in obese and hypogonadal men and not in healthy men.
That SHBG detail is the one worth carrying forward. It is the mechanism by which a total-testosterone panel can look like an improvement while the bioavailable fraction has not moved.
The case reports
Three published cases carry the individual-level signal, and all three involve tirzepatide or a GLP-1 agonist started recently.
A case report in Clinical Medicine Insights: Case Reports describes a 36-year-old woman with class III obesity who developed decreased sexual drive, genital dryness and anorgasmia after starting tirzepatide, with metabolic, hormonal, immunologic and haematologic causes ruled out by laboratory workup (PMID 40487373). Her Female Sexual Function Index score was 12.7 on the drug, rose to 28.7 after stopping it, and fell to 14.7 when the injection was resumed. Dechallenge followed by rechallenge is the strongest causality evidence a single case can produce.
A second report in Sexual Medicine documents anorgasmia following GLP-1 agonist initiation and works through candidate mechanisms with pharmacy consultation (PMID 40666108). The mechanism the authors considered most plausible was smooth-muscle vasoconstriction reducing oxygen delivery and blood flow to genital tissue, impairing engorgement and the smooth-muscle contractions involved in orgasm. They also raised hypothalamic GLP-1 receptor modulation reducing dopamine and norepinephrine signalling — the same reward-pathway argument the rodent studies make, arrived at independently.
The third widens the frame beyond sexual function. A Urology Case Reports paper describes a 40-year-old man who developed reproducible urinary frequency, penile pruritus, dysuria, pelvic and perineal pain and sexual dysfunction 3 to 4 weeks after starting tirzepatide (PMID 41716526). A comprehensive infectious evaluation was negative. Symptoms improved 4 days after discontinuation, resolved completely within 10 days, and had not recurred two weeks after the last injection. The authors describe the urologic adverse-effect profile of this drug class as poorly characterised.
What the current record does and does not cover
Four things follow from the state of the evidence, none of which is a treatment recommendation.
The measurement gap is the headline. Neither STEP, SURMOUNT nor TRIUMPH collected a validated sexual-function instrument — no FSFI, no IIEF — so the trial record that governs how these drugs are described contains no sexual-desire data at all. Every human number in this article comes from adverse-event databases, case reports, social-media analysis, or a single crossover trial in lean healthy men who were not the population taking these drugs for weight loss.
The retatrutide record is empty. No TRIUMPH readout has reported a sexual-function endpoint, and retatrutide appears in none of the reviews or meta-analyses above, which cover only approved agents. Community sources describing libido changes on retatrutide in August 2026 are self-reported and uncontrolled. What has been documented for the compound is catalogued in Retatrutide Side Effects, and the tingling and dysesthesia cluster reported this year sits in Retatrutide Dysesthesia.
The confounds are large and they run both ways. Rapid weight loss, aggressive caloric restriction, nausea, and improved body image all move sexual desire independently of any receptor mechanism, and they arrive simultaneously with the drug. The Obesity Pillars authors treat this as the reason the effect has stayed invisible rather than as a reason to dismiss it.
The onset and resolution windows in the case literature are short — 3 to 4 weeks to onset, 4 to 10 days to resolution after discontinuation. Anyone tracking their own response against the published record has that timeline to compare against, and the per-compound side-effect accounting is in Semaglutide Side Effects and Tirzepatide Side Effects.
